8-(4-Nitro-phenoxy)-octanoic acid methyl ester | 155148-01-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 8-(4-Nitro-phenoxy)-octanoic acid methyl ester
• 英文别名: Methyl 8-(4-nitrophenoxy)octanoate；methyl 8-(4-nitrophenoxy)octanoate
• CAS: 155148-01-9
• 化学式: C₁₅H₂₁NO₅
• 分子量: 295.335
• InChiKey: PQPNGBYJUOCMDD-UHFFFAOYSA-N

物化性质

• 沸点：
  417.7±25.0 °C(Predicted)
• 密度：
  1.132±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-(4-Nitro-phenoxy)-octanoic acid methyl ester 在 4-二甲氨基吡啶 、 氯化亚砜 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 4.0h， 生成 tert-butyl (tert-butyldimethylsilyl)oxy(8-(4-nitrophenoxy)octanoyl)carbamate
  参考文献：
  名称：

  The discovery and optimization of novel dual inhibitors of topoisomerase ii and histone deacetylase

  摘要：

  A novel class of podophyllotoxin derivatives have been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors. Their inhibitory activities towards histone deacetylases and Topo II and their cytotoxicities in cancer cell lines were evaluated. The aromatic capping group connection, linker length and zinc-binding group were systematically varied and preliminary conclusions regarding structure-activity relationships are discussed. Among all of the synthesized hybrid compounds, compound 24d showed the most potent HDAC inhibitory activity at a low nanomolar level and exhibited powerful antiproliferative activity towards HCT116 colon carcinoma cells at a low micromolar level. Further exploration of this series led to the discovery of potent dual inhibitor 32, which exhibited the strongest in vitro cytotoxic activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.09.023
• 作为产物：
  描述：

  8-溴辛酸 在 硫酸 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 8-(4-Nitro-phenoxy)-octanoic acid methyl ester
  参考文献：
  名称：

  基于XL019和vorinostat药效团融合的强力JAK2和HDAC双重抑制剂的设计与合成

  摘要：

  大多数癌症治疗的主要手段是同时用多种不同的药物同时阻断癌细胞中一种以上的致癌途径。能够通过两种靶向途径做到这一点，而不会通过一般机制（例如化学疗法）引起副作用，这可能会给患者带来好处。在这项工作中，我们通过设计和开发基于JAK2选择性抑制剂XL019和泛HDAC抑制剂vorinostat的两种类型的分子，描述了JAK-STAT和HDAC途径的新型双重抑制剂。这两个系列的化合物均具有低纳摩尔分子JAK2和HDAC1 / 6抑制作用的实例。在某些情况下，在保持HDAC6活性的同时，实现了良好的HDAC1选择性。通过对所有三种酶的分子对接研究来解释观察到的效价。一个例子69c对其他三种JAK家族蛋白JAK1，JAK3和TYK2具有16-25倍的选择性。许多化合物对一组4种实体肿瘤细胞系和4种血液学细胞系具有亚微摩尔效价，其中最有效的化合物45h对多发性骨髓瘤细胞系KMS-12-BM的细胞IC 50为70

  DOI：

  10.1016/j.ejmech.2018.09.024

文献信息

• Design, synthesis and In vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1
  作者：Adrian Folkes、S.David Brown、Lynne E. Canne、Jocelyn Chan、Erin Engelhardt、Sergey Epshteyn、Richard Faint、Julian Golec、Art Hanel、Patrick Kearney、James W. Leahy、Morrison Mac、David Matthews、Michael P. Prisbylla、Jason Sanderson、Reyna J. Simon、Zerom Tesfai、Nigel Vicker、Shouming Wang、Robert R. Webb、Peter Charlton

  DOI：10.1016/s0960-894x(02)00078-1

  日期：2002.4

  We have synthesized and evaluated a series of tetramic acid-based and hydroxvquinolinone-based inhibitors of plasminogen activator inhibitor-1 (PAI-1). These studies resulted in the identification of several compounds which showed excellent potency against PAI-1. The design, synthesis and SAR of these compounds are described. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat
  作者：Yu-yi Chu-Farseeva、Nurulhuda Mustafa、Anders Poulsen、Eng Chong Tan、Jeffrey J.Y. Yen、Wee Joo Chng、Brian W. Dymock

  DOI：10.1016/j.ejmech.2018.09.024

  日期：2018.10

  potencies against a panel of 4 solid tumor cell lines and 4 hematological cell lines with the most potent compound, 45h, having a cellular IC50 of 70 nM against the multiple myeloma cell line KMS-12-BM. Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated. Evidence of apoptosis with two compounds in 4 sold tumor cell lines is also presented

  大多数癌症治疗的主要手段是同时用多种不同的药物同时阻断癌细胞中一种以上的致癌途径。能够通过两种靶向途径做到这一点，而不会通过一般机制（例如化学疗法）引起副作用，这可能会给患者带来好处。在这项工作中，我们通过设计和开发基于JAK2选择性抑制剂XL019和泛HDAC抑制剂vorinostat的两种类型的分子，描述了JAK-STAT和HDAC途径的新型双重抑制剂。这两个系列的化合物均具有低纳摩尔分子JAK2和HDAC1 / 6抑制作用的实例。在某些情况下，在保持HDAC6活性的同时，实现了良好的HDAC1选择性。通过对所有三种酶的分子对接研究来解释观察到的效价。一个例子69c对其他三种JAK家族蛋白JAK1，JAK3和TYK2具有16-25倍的选择性。许多化合物对一组4种实体肿瘤细胞系和4种血液学细胞系具有亚微摩尔效价，其中最有效的化合物45h对多发性骨髓瘤细胞系KMS-12-BM的细胞IC 50为70
• The discovery and optimization of novel dual inhibitors of topoisomerase ii and histone deacetylase
  作者：Xuan Zhang、Bin Bao、Xiuhua Yu、Linjiang Tong、Yu Luo、Qingqing Huang、Mingbo Su、Li Sheng、Jia Li、Hong Zhu、Bo Yang、Xiongwen Zhang、Yi Chen、Wei Lu

  DOI：10.1016/j.bmc.2013.09.023

  日期：2013.11

  A novel class of podophyllotoxin derivatives have been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors. Their inhibitory activities towards histone deacetylases and Topo II and their cytotoxicities in cancer cell lines were evaluated. The aromatic capping group connection, linker length and zinc-binding group were systematically varied and preliminary conclusions regarding structure-activity relationships are discussed. Among all of the synthesized hybrid compounds, compound 24d showed the most potent HDAC inhibitory activity at a low nanomolar level and exhibited powerful antiproliferative activity towards HCT116 colon carcinoma cells at a low micromolar level. Further exploration of this series led to the discovery of potent dual inhibitor 32, which exhibited the strongest in vitro cytotoxic activity. (C) 2013 Elsevier Ltd. All rights reserved.